Home Tags Anti-TROP-2-SN-38

Tag: anti-TROP-2-SN-38

Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...

Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...

New Patents Awarded for Immunomedics’ Antibody-drug Conjugates Development Program

Earlier this week Immunomedics announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent 9,492,566, the 32nd U.S. patent protecting the...

Sacituzumab Govitecan Continues to show Positive Results in the Treatment of...

Updated results from a Phase II clinical study of sacituzumab govitecan, also known as IMMU-132, in patients with metastatic triple-negative breast cancer who had received...

New Data on Novel ADC For Solid Cancer Presented at Joint...

Clinical data on IMMU-132, an anti-TROP-2-SN-38 Anitbody-drug Conjugate currently being evaluated in patients with solid tumors, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and...

X